In July 2021 it was announced that Axion BioSystems had been acquired (for an undisclosed amount) by the Swedish firm Summa Equity - an entity explicitly in the acquisition business. Axion BioSystems had been working in the space of microelectrode array (MEA) data acquisition and analysis. With the Maestro MEA platform, functional activity assays on neural or cardiomyocyte cell networks can be tackled on the benchtop facilitating investigations in neurotoxicology, cardiac safety, in vitro disease modeling, and drug discovery. Scalability options from 12- to 96-wells and a new automation system, Maestro APEX, meets high throughput screening needs as well as assay development and follow-up studies - all with a single system. High-throughput optogenetic stimulation (Lumos) is an available option to researchers, enabling simultaneous fine-tuned cellular control and real-time functional activity assessment. Tying this all together is AxIS, the integrated acquisition and analysis program that makes every MEA assay from experiment start to completed analysis simple and straightforward.
